Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report) saw a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 2,080,000 shares, a drop of 18.1% from the October 31st total of 2,540,000 shares. Based on an average trading volume of 169,800 shares, the days-to-cover ratio is currently 12.2 days. Approximately 12.2% of the shares of the company are sold short.
Pulse Biosciences Stock Performance
NASDAQ:PLSE traded up $1.03 during mid-day trading on Friday, hitting $21.40. The company’s stock had a trading volume of 123,050 shares, compared to its average volume of 202,033. Pulse Biosciences has a fifty-two week low of $6.59 and a fifty-two week high of $22.69. The stock has a fifty day moving average of $17.31 and a 200-day moving average of $15.77.
Pulse Biosciences (NASDAQ:PLSE – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the company posted ($0.19) earnings per share.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Pulse Biosciences
Institutional Investors Weigh In On Pulse Biosciences
Large investors have recently made changes to their positions in the company. Franklin Resources Inc. bought a new stake in Pulse Biosciences during the 3rd quarter worth approximately $378,000. Barclays PLC boosted its stake in Pulse Biosciences by 361.4% in the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after purchasing an additional 23,738 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pulse Biosciences by 7.8% during the third quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the last quarter. State Street Corp increased its stake in shares of Pulse Biosciences by 17.8% in the third quarter. State Street Corp now owns 461,333 shares of the company’s stock valued at $8,092,000 after buying an additional 69,696 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pulse Biosciences in the third quarter valued at $588,000. Institutional investors own 76.95% of the company’s stock.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
- Five stocks we like better than Pulse Biosciences
- How Investors Can Find the Best Cheap Dividend Stocks
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- 3 Fintech Stocks With Good 2021 Prospects
- MarketBeat Week in Review – 11/25 – 11/29
- Investing in Travel Stocks Benefits
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.